The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, ...

Moderna Inc (MRNA) navigates a challenging quarter with significant cost reductions and strategic partnerships, despite a decline in COVID vaccine demand.

Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell ...

Australia's Victoria state on Wednesday unveiled plans to develop an onshore messenger-RNA (mRNA) vaccine manufacturing facility and launched three mass coronavirus immunisation centres to speed up ...

Moderna reported third-quarter financial results on Thursday. The transcript from the company's earnings call has been provided below.

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers ...